CA-PATIENT-SAFETY-MVMT
The Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, has selected five individuals for its inaugural Patient Safety Movement Foundation Healthcare Safety Fellowship program. The 12-month, part-time program is focused on providing education and continued development of skills for future healthcare leaders – positioning these stand-out individuals to serve as regional and global leaders in patient safety improvement for years to come.
“We are excited to launch our fellowship program and provide an opportunity to unify and prepare future leaders in patient safety,” said David B. Mayer, MD, CEO of the Patient Safety Movement Foundation. “These individuals have already demonstrated a commitment to improving healthcare, and we look forward to helping them design an individualized education plan that furthers their efforts and collectively helps us in our goal to achieve zero preventable patient deaths by 2030.”
Each of the five fellows will receive guidance from PSMF in designing an actionable plan that is tailored to their background, goals and the specific health needs of their region. In addition, fellows will have opportunities to interact and collaborate with an international network of patient safety and quality mentors, as well as facilitate and lead clinical coaching efforts with hospitals and healthcare organizations across the globe.
This year’s cohort participants include:
-
Luis Ramón Torres Torija Arguelles, MD, MBA
Dr. Luis Torres Torija Arguelles is a physician with a specialty in quality of clinical care from the Tecnológico de Monterrey in Mexico. He currently works as a quality and patient safety coordinator at Hospital Español in Mexico City, Mexico, where he is responsible for the management, design, evaluation, improvement and innovation of clinical care and patient safety processes, incorporating methodologies for continuous improvement and better communication. His efforts to implement all the Patient Safety Movement Foundation’s Actional Patient Safety Solutions have earned his hospital the 5-star Hospital recognition.
-
Carol Gunn, MD
Dr. Carol Gunn attended medical school at UC Davis and completed her internal medicine residency in Portland, Ore., followed by an additional year of training in occupational and environmental medicine at the University of Colorado. In 2007, she opened an independent occupational medicine practice. She thrives on working with individuals and groups advocating for system solutions – whether it be for health, wellness or patient safety.
-
Samar Hassan, PH, MSQ, CPHQ, FISQua
Samar Hassan holds a master’s degree in healthcare quality management and is a registered pharmacist and certified healthcare quality professional with the National Association for Healthcare Quality (NAHQ). In addition, Hassan has worked with the Health Care Accreditation Council (HCAC) in Jordan and the region’s quality improvement and patient safety institution since 2018, where she has been involved in the design, implementation and evaluation of standards for quality and patient safety across health and social care institutions. She has also participated and supported HCAC's advocacy and public awareness programs to synthesize professionals, the public and decision makers on adopting and implementing quality improvement approaches.
-
Elizabeth Namugaya Igaga, MD
Dr. Elizabeth Namugaya Igaga attended Makerere University in Kampala, Uganda, for medical school, as well as her master’s degree in anesthesia and critical care. She is currently doing her clinical practice at the Uganda Heart Institute. Igaga’s interest in patient safety was sparked after multiple firsthand experiences during residency that resulted in near misses or catastrophic outcomes. Since then, she has been passionate about fostering and building a culture of safety in perioperative care in Uganda.
-
Ebikapaye Okoyen, MD, MBBS, MBA, MHPM, FISQua
Dr. Ebikapaye Okoyen works in the Ministry of Health in Yenagoa, Nigeria, as the deputy director and state program manager for Saving One Million Lives Program for Results (SOML PforR) – a World Bank-funded, results-based program financing maternal and child health and nutrition aimed at improving quantity and quality of service. He is a fellow and member of several professional associations including the Nigerian Medical Association, the Society for Quality in Healthcare in Nigeria (SQHN) and is a certified SQHN Health Facility Surveyor with a specialist certificate on the Fundamentals of External Evaluation Surveying from the International Society for Quality in Healthcare (ISQua). He has also published papers in health services research.
To learn more about the Patient Safety Movement Foundation Healthcare Safety Fellowship, visit: https://patient.sm/PR-Fellowship .
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals, with more than three million deaths globally, as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero preventable patient harm and death. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005327/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
